These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26980172)

  • 21. Capecitabine-induced coronary vasospasm.
    Goldsmith YB; Roistacher N; Baum MS
    J Clin Oncol; 2008 Aug; 26(22):3802-4. PubMed ID: 18669470
    [No Abstract]   [Full Text] [Related]  

  • 22. [Long-Term Capecitabine Therapy Was Successful for Locally Advanced Breast Cancer Patient - Report of a Case].
    Adachi K; Sakurai K; Suzuki S; Kubota H; Hara Y; Fujiwara A; Enomoto K; Izu A; Sugitani M; Makishima M; Koshinaga T
    Gan To Kagaku Ryoho; 2018 Jan; 45(1):94-96. PubMed ID: 29362319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO).
    Cetin B; Benekli M; Turker I; Koral L; Ulas A; Dane F; Oksuzoglu B; Kaplan MA; Koca D; Boruban C; Yilmaz B; Sevinc A; Berk V; Uncu D; Harputluoglu H; Coskun U; Buyukberber S
    J Chemother; 2014 Oct; 26(5):300-5. PubMed ID: 24112786
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Highly durable response to capecitabine in patient with metastatic estrogen receptor positive breast cancer: A case report.
    Barchiesi G; Krasniqi E; Barba M; Giulia MD; Pizzuti L; Massimiani G; Ciliberto G; Vici P
    Medicine (Baltimore); 2019 Sep; 98(37):e17135. PubMed ID: 31517852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An overview of HER-targeted therapy with lapatinib in breast cancer.
    McArthur H
    Adv Ther; 2009 Mar; 26(3):263-71. PubMed ID: 19365626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of HER-2-targeted therapy on overall survival in patients with HER-2 positive metastatic breast cancer.
    Berghoff AS; Bago-Horvath Z; Dubsky P; Rudas M; Pluschnig U; Wiltschke C; Gnant M; Steger GG; Zielinski CC; Bartsch R
    Breast J; 2013; 19(2):149-55. PubMed ID: 23350584
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2.
    Ryan Q; Ibrahim A; Cohen MH; Johnson J; Ko CW; Sridhara R; Justice R; Pazdur R
    Oncologist; 2008 Oct; 13(10):1114-9. PubMed ID: 18849320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer].
    Ismaili N; Belbaraka R; Elomrani A; Khouchani M; Tahri A
    Presse Med; 2013 Nov; 42(11):1461-8. PubMed ID: 23721860
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chromosome 17 polysomy without HER2 amplification does not predict response to lapatinib in metastatic breast cancer--letter.
    Moelans CB; de Weger RA; van Diest PJ
    Clin Cancer Res; 2010 Dec; 16(24):6177; author reply 6178. PubMed ID: 21169261
    [No Abstract]   [Full Text] [Related]  

  • 30. Reversible severe fatty liver induced by capecitabine: A case report.
    Jiang Y; He Q; Li S; Shi C; Yang X
    Medicine (Baltimore); 2017 Nov; 96(46):e8547. PubMed ID: 29145260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A life-threatening drug-drug interaction between capecitabine and brivudine in a patient with metastatic breast cancer.
    Tsifi A; Papaxoinis G; Diamantopoulos P; Mantzourani M; Antoniadou V; Halioti A; Gogas H
    J Chemother; 2019; 31(7-8):424-427. PubMed ID: 31516092
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lapatinib-induced hepatitis: a case report.
    Peroukides S; Makatsoris T; Koutras A; Tsamandas A; Onyenadum A; Labropoulou-Karatza C; Kalofonos H
    World J Gastroenterol; 2011 May; 17(18):2349-52. PubMed ID: 21633602
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lapatinib for breast cancer: a review of the current literature.
    MacFarlane RJ; Gelmon KA
    Expert Opin Drug Saf; 2011 Jan; 10(1):109-21. PubMed ID: 21091041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors.
    Dennie TW; Fleming RA; Bowen CJ; Dar MM; Alberti D; Oliver K; Loconte N; Mulkerin D; Holen KD
    Clin Colorectal Cancer; 2011 Mar; 10(1):57-62. PubMed ID: 21609937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
    Cameron DA; Stein S
    Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coronary artery spasm induced by capecitabine.
    Sestito A; Sgueglia GA; Pozzo C; Cassano A; Barone C; Crea F; Lanza GA
    J Cardiovasc Med (Hagerstown); 2006 Feb; 7(2):136-8. PubMed ID: 16645374
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
    Martin M; Bonneterre J; Geyer CE; Ito Y; Ro J; Lang I; Kim SB; Germa C; Vermette J; Wang K; Wang K; Awada A
    Eur J Cancer; 2013 Dec; 49(18):3763-72. PubMed ID: 23953056
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early-onset brain metastases in a breast cancer patient after pathological complete response to neoadjuvant chemotherapy.
    Shimada K; Ishikawa T; Yoneyama S; Kita K; Narui K; Sugae S; Shimizu D; Tanabe M; Sasaki T; Chishima T; Ichikawa Y; Endo I
    Anticancer Res; 2013 Nov; 33(11):5119-21. PubMed ID: 24222158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms of lapatinib resistance in HER2-driven breast cancer.
    D'Amato V; Raimondo L; Formisano L; Giuliano M; De Placido S; Rosa R; Bianco R
    Cancer Treat Rev; 2015 Dec; 41(10):877-83. PubMed ID: 26276735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.
    Jo Chien A; Rugo HS
    Cancer Treat Res; 2009; 151():197-215. PubMed ID: 19593514
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.